Here’s how the data stack up, why chart watchers see upside, and where an overlooked presale, Remittix (RTX), could steal ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.